Back to results
US 7,888,067 B2Granted
Recombinant human factor IX and use thereof
AssigneeShu-Wha Lin
InventorsShu-Wha Lin, Chia-Ni Lin, Hua-Lin Wu, Guey-Yueh Shi
Life of this patent
Estimating the term…
Abstract
The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.
Claims6
An isolated nucleic acid comprising the nucleic acid sequence of SEQ ID NO:
- 14, wherein said nucleic acid encodes a recombinant human Factor IX protein (FIX), that comprises the amino acid sequence of SEQ ID NO:
- 7, except for amino acid substitution(s) at one or more positions of SEQ ID NO:7 selected from the group consisting of:
- substitution at position 86, substitution at position 277, substitution at positions 86 and 277, substitution at positions 86 and 338, substitution at positions 277 and 338, and substitution at positions 86, 277 and 338.
A method for generating a human Factor IX (FIX) protein in vivo comprising:
- (a) constructing a vector carrying a nucleic acid encoding the human FIX protein;
- and (b) administering the vector to a mammal, wherein the human FIX protein comprises the amino acid sequence of SEQ ID NO:
- 7, except for amino acid substitution(s) at one or more positions of SEQ ID NO:
- 7 selected from the group consisting of:
- substitution at position 86, substitution at position 277, substitution at positions 86 and 277, substitution at positions 86 and 338, substitution at positions 277 and 338, and substitution at positions 86, 277 and 338.
2 more elements
Dependencies are inferred from the claim text.